Allyson M. Maur
Professional Bio
Allyson advises on regulatory issues affecting diagnostics developers, biopharma manufacturers, and clinical laboratories, including CLIA/CLEP and FDA regulatory advice, MLR and MRC review of marketing and promotional materials, clinical studies, global data privacy issues, ethics & compliance, commercial contracting, commercial litigation and more.
HHS Proposed Rule May Enhance HIPAA Security but Leaves AI Questions Open
Password Protected ·
Ounce of Prevention: Is It Time to Perform a Security Risk Assessment?
Password Protected ·
Illinois Jumps on the Food Ingredient ‘Banned’ Wagon
One-Stop Shop ·